Ovarian Cancer

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from the ROSELLA trial and the future of relacorilant in platinum-resistant ovarian cancer.

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

The FDA granted fast track designation to PHST001 for patients with ovarian cancer.

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.